Immunosuppression for Mooren's ulcer: Evaluation of the stepladder approach - Topical, oral and intravenous immunosuppressive agents

British Journal of Ophthalmology

Volumn 97, Issue 11, 2013, Pages 1391-1394

  Ashar, Jatin N ^a   Mathur, Anurag ^a   Sangwan, Virender S ^a  

^a L V PRASAD EYE INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISOLONE ACETATE; RANITIDINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CORNEA PERFORATION; CORNEA RODENT ULCER; CORNEA THICKNESS; CORNEA TRANSPLANTATION; DISEASE CONTROL; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDIA; KERATOPLASTY; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PEPTIC ULCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECONDARY INFECTION; TERTIARY HEALTH CARE;

CORNEA; IMMUNOLOGY;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS; CORNEAL ULCER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; MALE; METHOTREXATE; MIDDLE AGED; PREDNISOLONE; PRODRUGS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84888636470     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2012-302627     Document Type: Article

References (17)

1. Wood T, Kaufman H. Mooren's ulcer. Am J Ophthalmol 1971;71:417-22.
2. Murray PI, Rahi AH. Pathogenesis of Mooren's ulcer: some new concepts. Br J Ophthalmol 1984;68:182-7. (Pubitemid 15134724)
3. Brown SI, Mondino BJ. Therapy of Mooren's ulcer. Am J Ophthalmol 1984;98:1-6. (Pubitemid 14089526)
4. Foster CS. Systemic immunosuppressive therapy for progressive bilateral Mooren's ulcer. Ophthalmology 1985;92:1436-9. (Pubitemid 16228038)
5. Cordero-Coma M, Benito MF, Fuertes CL, et al. Adalimumab for Mooren's ulcer. Ophthalmology 2009;116:1589, 1589.e1.
6. Erdem U, Kerimoglu H, Gundogan FC, et al. Treatment of Mooren's ulcer with topical administration of interferon alfa 2a. Ophthalmology 2007;114:446-9. (Pubitemid 46282964)
7. Sangwan VS, Zafirakis P, Foster CS. Mooren's ulcer: current concepts in management. Indian J Ophthalmol 1997;45:7-17.
8. Agrawal V, Kumar A, Sangwan V, et al. Cyanoacrylate adhesive with conjunctival resection and superficial keratectomy in Mooren's ulcer. Indian J Ophthalmol 1996;44:23-7. (Pubitemid 126516455)
9. Wakefield D, Robinson LP. Cyclosporin therapy in Mooren's ulcer. Br J Ophthalmol 1987;71:415-17. (Pubitemid 17082191)
10. Jeurissen ME, Boerbooms AM, van de Putte LB, et al. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight-week randomized, double-blind trial. Arthritis Rheum 1991;34:961-72.
11. Vencovský J, Jarosová K, Machácek S, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000;29:95-102.
12. De Groot K, Rasmussen N, Bacon PA, et al . Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9. (Pubitemid 41117433)
13. Young AL, Rao SK, Cheng LL, et al. Combined intravenous pulse methylprednisolone and oral cyclosporine A in the treatment of corneal graft rejection: 5-year experience. Eye 2002;16:304-8. (Pubitemid 34618830)
14. McCluskey P, Wakefield D. Intravenous pulse methylprednisolone in scleritis. Arch Ophthalmol 1987;105:793-7. (Pubitemid 17082541)
15. Wakefield D, McCluskey P, Penny R. Intravenous pulse methylprednisolone therapy in severe inflammatory eye disease. Arch Ophthalmol 1986;104:847-51. (Pubitemid 16114932)
16. Durrani K, Papaliodis GN, Foster CS. Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety. Ophthalmology 2004;111:960-5. (Pubitemid 38586692)
17. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-57. (Pubitemid 32799338)